Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Pharma & Biotech

Neurocrine Biosciences strengthens INGREZZA case with functional improvement data

Mild TD can still disrupt work and independence. Neurocrine’s INGREZZA data raises pressure to rethink when treatment begins.

Read More
Pharma & Biotech

Accro Bioscience’s $50m round signals growing interest in targeted IBD immunology

IBD needs safer oral options. Accro’s $50 million raise puts RIPK2 inhibition closer to a decisive clinical test.

Read More
Pharma & Biotech

Can IBI3002 help Innovent Biologics challenge the next wave of type 2 inflammation therapies?

Bispecific antibodies are moving beyond oncology. Innovent’s autoimmune pipeline now faces the harder test of clinical durability.

Read More
Pharma & Biotech

Could Caliway’s CBL-514 become a metabolic add-on to semaglutide and tirzepatide?

GLP-1 drugs drive weight loss, but rebound and body composition gaps remain. Caliway’s CBL-514 may test the next obesity frontier.

Read More
Pharma & Biotech

Can Leads Biolabs turn Opamtistomig into a frontline EP-NEC treatment contender?

EP-NEC has no approved drug worldwide. Leads Biolabs now has to prove Opamtistomig can turn rare-tumor urgency into regulatory momentum.

Read More
Pharma & Biotech

How Full-Life Technologies is using US$150m to push beyond platform promise

Radiopharma needs more than promising targets. Full-Life’s US$150m raise puts actinium-225 supply and clinical execution in focus.

Read More
Representative image: A nebulized respiratory therapy setup illustrates the clinical focus behind AeroRx Therapeutics’ AERO-007 Phase 2a COPD data, as researchers evaluate whether once-daily LABA+LAMA nebulized treatment can address persistent delivery challenges in chronic obstructive pulmonary disease care.
Pharma & Biotech

Can AeroRx turn nebulized COPD treatment into a first-line dual bronchodilator category?

COPD care relies on handheld inhalers, but many patients struggle with delivery. AeroRx is testing whether nebulized dual therapy can close that gap.

Read More
Representative image: Clinicians reviewing lung cancer imaging and genomic test results, reflecting Bayer’s HYRNUO FDA Priority Review and the growing role of precision oncology in HER2-mutated non-small cell lung cancer treatment.
Pharma & Biotech

Why Bayer’s HYRNUO first-line FDA review could reshape HER2-mutated NSCLC treatment sequencing

Bayer has FDA momentum in HER2-mutated lung cancer. The harder test is whether HYRNUO can move earlier without stronger survival data.

Read More
Representative image of neonatal gene therapy research in a modern clinical setting. iECURE’s ECUR-506 data have sharpened interest in whether targeted gene insertion could reduce hyperammonemic events in infants with neonatal-onset OTC deficiency.
Pharma & Biotech

Is iECURE’s infant gene editing therapy quietly changing the OTC deficiency playbook?

A rare disease gene editing signal is only the start. iECURE now has to prove ECUR-506 can sustain OTC deficiency control.

Read More
Representative image: Scientists analyze CRISPR gene-editing and liver-targeted cardiometabolic research data in a biotech laboratory, reflecting Scribe Therapeutics’ push to advance epigenetic silencing for durable LDL-C reduction.
Pharma & Biotech

Scribe Therapeutics brings specificity challenge into focus for CRISPR cardiometabolic drugs

CRISPR can lower cholesterol. The harder test is whether Scribe can make durability, precision, and scalability work in common disease.

Read More